SCHEMBL257940

SCHEMBL257940

Nc1cc(Oc2cccc(F)c2)ccc1B(O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 1/20 0.43
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
MITF O75030 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
GFER P55789 1/20 0.42
KMT2A Q03164 1/20 0.42
NLRP1 Q9C000 1/20 0.42
NOD2 Q9HC29 1/20 0.42
SLC6A2 P23975 5/20 0.41
SLC6A4 P31645 5/20 0.41
SLC6A3 Q01959 4/20 0.41
NR4A1 P22736 1/20 0.41
KCNH2 Q12809 1/20 0.40
SCN3A Q9NY46 1/20 0.40
F10 P00742 1/20 0.39
MGLL Q99685 1/20 0.38
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3790117 0.85 CA1 (0.53) ALDH1A1SMN1; SMN2MEN1MITFGAA
SCHEMBL10269424 0.83 MAOA (0.40) ALDH1A1SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL177751 0.83 SLC6A2 (0.42) GCKSLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL177644 0.82 KCNH2 (0.41) GCKALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL177562 0.81 FFAR1 (0.43) GCKSLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL14537743 0.79 SLC6A2 (0.40) GCKSLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL177690 0.79 ENPP2 (0.44) ALDH1A1SMN1; SMN2MEN1MAPTKMT2A
SCHEMBL177376 0.78 AR (0.45) KMT2ASLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL10269109 0.78 MGLL (0.39) GCKALDH1A1MEN1MAPTKMT2A
SCHEMBL24751466 0.77 MAPT (0.56) GCKALDH1A1SMN1; SMN2MEN1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2404607-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2012-01-11 EP disclosed
EP-2399585-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2011-12-28 EP disclosed
EP-2399584-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2011-12-28 EP disclosed
US-7947663-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2011-05-24 US disclosed
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 GCK 2657/4885ALDH1A1 444/4885SMN1; SMN2 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.